DrugMar 8, 2023
Simvastatin Tablets, USP, 10 mg recall — FDA D-0409-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
Latest records
Latest recalls — page 614
The newest recall records with useful source details are listed here.
DrugMar 8, 2023
Simvastatin Tablets USP 80 mg recall — FDA D-0412-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Simvastatin Tablets USP 5 mg recall — FDA D-0408-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Glycopyrrolate Injection, USP 4 mg/20 mL (0.2 mg/mL) 20 mL Multiple Dose Vial, 10vial carton recall — FDA D-0399-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Daptomycin for Injection 350 mg/vial recall — FDA D-0381-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Daptomycin for Injection 500 mg per vial, Single-dose vial recall — FDA D-0382-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Accord Healthcare Phenylephrine Hydrochloride Injection, USP 100 mg/10 mL (10 mg/mL) recall — FDA D-0403-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
The Harvard Drug Group Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose recall — FDA D-0432-2023
Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Class IIFDA: TerminatedThe Harvard Drug Group
DrugMar 8, 2023
Simvastatin Tablets USP 20 mg recall — FDA D-0410-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Nephron Sterile Compounding Center Norepinephrine Bitartrate in 0.9% Sodium Chloride recall — FDA D-0357-2023
Lack of Assurance of Sterility
Class IIFDA: TerminatedNephron Sterile Compounding Center LLC
DrugMar 8, 2023
rOPINIRole Tablets USP 1 mg*, 100-count bottle recall — FDA D-0427-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Accord Healthcare Succinylcholine Chloride Injection, USP, 200 mg/10 mL (20 mg/mL), 10 mL recall — FDA D-0413-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Nephron Sterile Compounding Center Phenylephrine HCl Injection, USP, 0.4 mg/10 mL recall — FDA D-0360-2023
Lack of Assurance of Sterility
Class IIFDA: TerminatedNephron Sterile Compounding Center LLC
DrugMar 8, 2023
DuPont Nutrition USA Avicel PH- 101 NF, Microcrystalline Cellulose, NF, Ph recall — FDA D-0349-2023
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Class IIIFDA: TerminatedDuPont Nutrition USA, Inc.
DrugMar 8, 2023
Nephron Sterile Compounding Center Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 recall — FDA D-0355-2023
Lack of Assurance of Sterility
Class IIFDA: TerminatedNephron Sterile Compounding Center LLC
DrugMar 8, 2023
Pirfenidone Tablets 801 mg recall — FDA D-0420-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
BusPIRone Hydrochloride Tablets USP 7.5 mg, 100-count bottle recall — FDA D-0375-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
rOPINIRole Tablets USP 3 mg*, 100-count bottle recall — FDA D-0429-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
rOPINIRole Tablets USP 5 mg* 100-count bottle recall — FDA D-0431-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
BusPIRone Hydrochloride Tablets USP, 10 mg 500-count bottle recall — FDA D-0378-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
rOPINIRole Tablets USP 2 mg*, 100-count bottle recall — FDA D-0428-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Accord Healthcare Phenylephrine Hydrochloride Injection, USP 10 mg/mL recall — FDA D-0401-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
DuPont Nutrition USA Avicel PH- 102 NF, Microcrystalline Cellulose, NF, Ph recall — FDA D-0350-2023
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Class IIIFDA: TerminatedDuPont Nutrition USA, Inc.
DrugMar 8, 2023
Rosuvastatin Tablets, USP 20 mg* recall — FDA D-0406-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
October 2026110 records · 3 categoriesSeptember 2026364 records · 4 categoriesAugust 2026302 records · 4 categoriesJuly 2026370 records · 4 categoriesJune 2026376 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categoriesDecember 2025389 records · 4 categoriesNovember 2025326 records · 4 categories